Filing Flows › AbCellera Biologics (ABCL) › Q3 2026 › vs Q3 2025
AbCellera Biologics (ABCL) Q3 2026 vs Q3 2025 (year over year)
AbCellera Biologics's revenue rose $1.7M (+19%) from $9.0M in Q3 2025 to $10.6M in Q3 2026. The biggest changes: Research fees +$1.7M (+20%); Licensing and royalty revenue −$48K (-35%).
AbCellera Biologics, Q3 2026: revenue $10.6M (+19% year over year), operating margin -501.1%, net loss $40.8M, operating cash flow $26.9M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 237.8% | -687.0% | +924.8 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Research fees | $10.5M | $8.8M | $1.7M | +20% |
| Licensing and royalty revenue | $90K | $138K | −$48K | -35% |
| Revenue | $10.6M | $9.0M | $1.7M | +19% |
| Other income, net | $10.5M | $7.5M | $3.0M | +40% |
| Income tax benefit | $2.1M | $11.6M | −$9.6M | -82% |
| Net loss | $40.8M | $57.1M | −$16.4M | -29% |
| Costs & expenses | $64.0M | $85.2M | −$21.3M | -25% |
| Operating costs | $64.0M | $85.2M | −$21.3M | -25% |
| Research & development | $43.5M | $55.0M | −$11.5M | -21% |
| Other operating costs | $6.8M | $5.2M | $1.6M | +30% |
| Operating cash sources | $67.7M | $4.5M | $63.1M | 15× |
| Depreciation & amortization | $6.8M | $5.2M | $1.6M | +30% |
| Share-based compensation | $11.7M | $13.9M | −$2.2M | -16% |
| Working capital & other | $49.2M | −$14.6M | $63.8M | — |
| Net loss absorbed | $40.8M | $57.1M | −$16.4M | -29% |
| Operating cash flow | $26.9M | −$52.6M | $79.5M | — |
| Free cash flow (OCF − capex) | $25.3M | −$61.5M | $86.8M | — |
| Capital expenditures | $1.6M | $8.9M | −$7.3M | -82% |
Questions
How much did AbCellera Biologics's revenue grow year over year in Q3 2026?
AbCellera Biologics's revenue rose $1.7M (+19%) from $9.0M in Q3 2025 to $10.6M in Q3 2026.
What drove AbCellera Biologics's revenue change in Q3 2026?
Research fees +$1.7M (+20%); Licensing and royalty revenue −$48K (-35%).